Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730846 · ClinicalTrials.gov registry record · Phase 2
Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01730846 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 35 participants.
The verdict
NCT01730846, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.
Interventions
- DRUG Placebo
- DRUG Doxazosin 4mg/day
- DRUG Doxazosin 8mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730846
The ClinicalTrials.gov registry entry for NCT01730846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01730846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730846 about?
NCT01730846 is a clinical study titled "Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?". The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.
What is the current status of trial NCT01730846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2013-02. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01730846?
The interventions under investigation include: Placebo (DRUG), Doxazosin 4mg/day (DRUG), Doxazosin 8mg/day (DRUG).
Who is sponsoring clinical trial NCT01730846?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.